Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy

Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet